Reloxa Drug Interactions

Rabeprazole sodium, as is the case with other members of the proton pump inhibitors (PPI) class of compounds, is metabolised through the cytochrome P450 (CYP450) hepatic drug metabolising system.
Studies in healthy subjects have shown that Rabeprazole sodium does not have clinically significant interactions with other drugs metabolised by the CYP450 system, such as warfarin, phenytoin, theophylline or diazepam. Rabeprazole sodium produces a profound and long lasting inhibition of gastric acid secretion. An interaction with compounds whose absorption is pH dependent may occur therefore the potential for such interaction was investigated.
Coadministration of Rabeprazole sodium results in a 33% decrease in ketoconazole levels and a 22% increase in trough digoxin levels in normal subjects. Therefore, individual patients may need to be monitored to determine if a dosage adjustment is necessary when such drugs are taken concomitantly with Rabeprazole sodium (Reloxa). In clinical trials, antacids were used concomitantly with the administration of Rabeprazole sodium (Reloxa) and in a specific study designed to define this interaction, no interaction with liquid antacids was observed.
There was no clinically relevant interaction with food.